European Archives - Page 445 of 1109 - European Medical Journal

Cotard’s Delusion with Sequelae of Adult Onset Failure to Thrive: A Case Report

Patients can present with chief complaints and symptoms that differ from the eventual diagnoses. The differences between aetiologies versus complications must be appreciated through careful evaluation and use of clinical investigations, laboratory testing, trial of hypotheses, and clinical gestalt.

Interview: Yann Le Cam

Yann Le Cam Chief | Executive Officer, EURORDIS-Rare Diseases Europe. The conference happens every 2 years and the purpose is to formulate strategies at a national, international, and European level. The conference also provides an opportunity to look at legislative and non-legislative policies and learn about the latest research. The scope is broad, covering the entire spectrum of rare diseases.

Neratinib as a Potential Therapeutic for Mutant RAS and Osimertinib-Resistant Tumours

Neratinib was developed as an irreversible catalytic inhibitor of ERBB2, which also acts to inhibit ERBB1 and ERBB4. Neratinib is U.S. Food and Drug Administration (FDA)-approved as a neo-adjuvant therapy for use in HER2+ breast cancer.

The Journey to Drug Development

This week, Joubert Gama joins our EMJ Podcast host, Jonathan Sackier to discuss innovations in pharmaceutical sciences and drug developments.

EMJ Cardiology 10 [Supplement 6] 2022

This article discussed cigarette smoking as a major risk factor for cardiovascular disease (CVD). Looking through the lens of toxic cigarette smoke constituents, the review described the oxidative stress and inflammatory responses induced following their entry into the bloodstream.

Heated Tobacco Products and Cardiovascular Disease: A Narrative Review of Peer-Reviewed Publications

This article discussed cigarette smoking as a major risk factor for cardiovascular disease (CVD). Looking through the lens of toxic cigarette smoke constituents, the review described the oxidative stress and inflammatory responses induced following their entry into the bloodstream.

Pharmacovigilance past, present and future

Marc and Helena are joined by Pav Rishiraj, Director and Head of Pharmacovigilance, Ipsen, to shed light on this often-overlooked field.

Elevating pharma’s parental leave policies

With continued drive for equality across the pharma industry, the issue of parental leave is coming to the fore. But is the industry’s approach sufficiently transparent, and what more can be done?

Five Years of World Atopic Dermatitis Day

This podcast mini-series, celebrating World Atopic Dermatitis Day 2022, explores the impact of the global awareness day, looking at how far we have come since its inception 5 years ago.

Innovations in Oncology

This week, EMJ podcast host Jonathan Sackier is joined by Sir Michael Brady, discussing his work in oncological innovations. Listen now!